ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

炭酸ランタン(Ⅲ)N水和物

Lanthanum carbonate anhydrous

HCID 168924
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
54451-24-0
標準SMILES
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3]
InChIKey
NZPIUJUFIFZSPW-UHFFFAOYSA-H
分子式
C3La2O9
平均分子量
457.84 g/mol
単同位体質量
457.76696

概要

Lanthanum carbonate is a phosphate binder marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects. It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.

名称と識別子

優先名称
Lanthanum carbonate anhydrous
IUPAC
bis(lanthanum(3+));tricarbonate
現地名
炭酸ランタン(Ⅲ)N水和物
英語名
Lanthanum carbonate
分子式
CH4LaO4
分子量
218.94

名称と別名

Lanthanum Carbonate587-26-8FoznolPhosblocLanthanum sesquicarbonateCarbonic acid, lanthanum(3+) salt (3:2)Lanthanum(3+) carbonateLanthanum (III) carbonateLanthanum carbonate anhydrous0M78EU4V9HDTXSID30890512Lanthanum carbonate (la2(co3)3)
名称をさらに表示
炭酸ランタン(Ⅲ)N水和物炭酸ランタンN水和物, 99.5%炭酸ランタン水和物/ 99.9%炭酸ランタン水和物/ 99.99%炭酸ランタン(III)水和物, 99.9% (REO)炭酸ランタン水和物炭酸ランタン水和物 (JAN)Lanthanum(III) carbonate hydrateC3H2La2O10LANTHANUM CARBONATE HYDRATELANTHANUM CARBONATE N-HYDRATELanthanum carbonate, GR 99.9%LANTHANUM(+3)CARBONATE HYDRATELANTHANUM CARBONATE HYDRATE ARLanthanum(III) carbonate xhydrateLanthanum Carbote Hydrate 99.5% AR
Lanthanum(3) carbonateRefChem:55453DTXCID201030387209-599-5611-146-5490D9F069TBAY77-1931Dilanthanum tricarbonate hydrate

物性

構造計算による物性

極性表面積
190 Ų
水素結合供与体数
0
水素結合受容体数
9
回転可能結合数
0
重原子数
14
形式電荷
0
複雑度
18.8

実験および物理化学的性質

Density2.6
Color/FormWhite powder
Solubility · 3 件

Practically insoluble.

Soluble in acids

Practically insoluble in water

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physical DescriptionCBI; Large Crystals; Dry Powder

物理化学的性質

比重(密度)
2.6 · 2.6-2.7
貯蔵温度
Inert atmosphere,Room Temperature
外見
粉末・塊
水溶解度
酸に可溶。水に不溶。
Merck
14 · 14,5364
InChI
1S/3CH2O3.2La.H2O/c3*2-1(3)4;;;/h3*(H2,2,3,4);;;1H2/q;;;2*+3;/p-6
InChIKey
AFCUGQOTNCVYSW-UHFFFAOYSA-H
SMILES
O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O
CAS データベース
54451 · 54451-24-0(CAS DataBase Reference)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

This chemical does not meet GHS hazard criteria for 6.4% (3 of 47) of reports.

Warning

H315 (93.6%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 47 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

This chemical does not meet GHS hazard criteria for 83.3% (10 of 12) of all reports.

危険有害性情報

Regulatory Information · 2 件

Carbonic acid, lanthanum(3+) salt (3:2) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Carbonic acid, lanthanum(3+) salt (3:2) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

REACH registered substance: Dilanthanum tricarbonate (EC: 209-599-5)

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl lanthanum carbonate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Hazard Classes and Categories · 2 件

Skin Irrit. 2 (93.6%)

Skin Irrit. 2 (16.7%)

安全と保護具

Storage ConditionsStore at 25 °C (77 °F): excursions permitted to 15-30 °C (59-86 °F)

化学と産業

薬理情報

ATC Code · 2 件

V - Various

QV - Various

Protein Binding_In vitro_, lanthanum is highly bound (>99%) to human plasma proteins, including human serum albumin, α1-acid glycoprotein, and transferrin.
Pharmacodynamics · 1 件

In vitro studies have shown that lanthanum binds phosphate in the physiologically relevant pH range of 3 to 7 - in simulated gastric fluid, lanthanum binds approximately 97% of the available phosphate at pH 3-5 and 67% at pH 7, when lanthanum is present in a two-fold molar excess to phosphate. Bile acids have not been shown to affect the phosphate binding affinity of lanthanum. In order to bind dietary phosphate, lanthanum carbonate must be administered with or immediately after meals. In comparison to [sevelemer], another common phosphate binder, lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia.

Mechanism of Action · 3 件

Lanthanum carbonate is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the gastrointestinal (GI) tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.

Lanthanum carbonate dissociates in the acid environment of the upper GI tract to release lanthanum ions that bind dietary phosphate released from food during digestion. Lanthanum carbonate inhibits absorption of phosphate by forming highly insoluble lanthanum phosphate complexes, consequently reducing both serum phosphate and calcium phosphate product.

The carbonate salt of lanthanum is practically insoluble in water but dissociates in the acidic environment of the upper GI tract to release trivalent lanthanum ions, which bind dietary phosphates released during digestion, thereby forming highly insoluble lanthanum phosphate complexes. Consequently, phosphate absorption, serum phosphorus concentrations, and serum calcium times phosphorus product (Ca X P) are reduced. Lanthanum ions have a high affinity for phosphate; in vitro studies indicate that when lanthanum is present at pH 3-5 (pH corresponding to that of gastric fluid) in twofold molar excess to phosphates, the drug binds about 97% of available phosphates.

関連反応

6 件
反応記録を作成
HRID 129900 の反応式
HRID 129900反応物として
HRID 1755960 の反応式
HRID 1755960生成物として
HRID 1755961 の反応式
HRID 1755961生成物として
HRID 1755962 の反応式
HRID 1755962生成物として
HRID 1856446 の反応式
HRID 1856446反応物として
HRID 2405530 の反応式
HRID 2405530生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
54451-24-0、587-26-8
PubChem CID
168924
DTXSID
DTXSID30890512
ChEMBL
CHEMBL2096647
UNII
0M78EU4V9H
EC Number
209-599-5、611-146-5

化学的性質

化学的特性white powder(s) [STR93]

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 2 件

Drugs known to interact with antacids should not be administered within 2 hours of a lanthanum carbonate dose. Potential pharmacokinetic interaction (insoluble complex formation).

... Twelve patients randomly received in a crossover manner a single oral dose of ciprofloxacin 750 mg alone and plus lanthanum carbonate 1 g three times daily with meals for six doses, with a washout interval of 7 to 14 d. Serial blood and urine samples were collected for 24 hr after ciprofloxacin administration, and ciprofloxacin concentrations were determined using reverse-phase HPLC. Pharmacokinetic parameters of ciprofloxacin were calculated by noncompartmental methods, and the effect of lanthanum on ciprofloxacin pharmacokinetic parameters was assessed using ANOVA. Lanthanum decreased (P < 0.001) the mean ciprofloxacin area under the plasma concentration-time curve by 54% and the maximum plasma concentration by 56%. The 24-hr urinary recovery of ciprofloxacin was reduced by 52% by lanthanum (P < 0.001). No statistically significant differences in ciprofloxacin time to maximum plasma concentration, elimination half-life, and renal clearance occurred between the two arms. Lanthanum carbonate significantly reduces the systemic exposure to orally administered ciprofloxacin. Concomitant administration of both drugs should be avoided to prevent possible suboptimal response to ciprofloxacin.

Human Toxicity Excerpts · 3 件

/CASE REPORTS/ A 75-year-old woman was admitted with febrile confusion and abdominal pain. She was taking medications that included lanthanum carbonate. Examination, biology, a cerebral scan, and a review of her medications could not explain the confusion. The plain film of the abdomen revealed multiple diffuse calcium-like deposits throughout the digestive tract. The plasma levels of lanthanum were higher than normal. The confusion resolved after discontinuation of the lanthanum carbonate. This case raises the problem of the potential role played by lanthanum tablet residue in the genesis or aggravation of diverticular flare-up and the problem of the potential permeability of the blood-brain barrier with lanthanum use in case of its digestive accumulation, leading to increased serum concentrations.

/CASE REPORTS/ ... A 77-year-old man was admitted to a hospital for renal failure caused by complete obstructive ureterolithiasis in the solitary kidney. Hemodialysis was indicated due to elevated renal parameters (urea 28.0 mmol/L, serum creatinine 1079 umol/L, phosphorus 2.45 mmol/L). Treatment with lanthanum carbonate was started in order to normalize serum phosphate levels. Surgical treatment of ureteral obstruction was necessary but the patient presented with hemodynamically significant supraventricular tachycardia. The ECG proved atrial flutter that was the indication to electrical cardioversion by cardiologists. Therefore, transesophageal echocardiography had to be carried out to exclude intracardial thrombi; these were not detected. The echocardiography also demonstrated an inexplicable finding on the thoracic aorta, and thus, computed tomography of the aorta was performed. The CT scan did not reveal any significant pathology of the aorta. However, a high-contrast substance of unknown origin and significance was captured in the stomach. /Investigators/ performed an X-ray of lanthanum pills in a vial and detected the radio-opacity of lanthanum itself, even without calcium and phosphate. This confirmed our suspicion that the high-contrast metallic-like substance in the stomach was a tablet of lanthanum. ...

/EPIDEMIOLOGY STUDIES/ A specified subset of data from four Phase III clinical trials and subsequent extension studies is presented, in order to assess the effects of lanthanum carbonate on the liver. Hepatic biochemical tests for alanine transaminase, aspartate aminotransferase, alkaline phosphatase and bilirubin were performed. Adverse events classified as "liver and biliary system events" were recorded. In the four initial clinical trials, lanthanum carbonate was not associated with any adverse changes in transaminases or bilirubin. The incidence and nature of adverse events associated with the liver during lanthanum carbonate treatment was similar to that in the comparator groups. For patients who enrolled into the subsequent long-term follow-up study (up to 6 years of treatment), changes in transaminases were not clinically relevant and mean values were similar to those observed in the earlier trials. Overall, there was no increase in the incidence of adverse events associated with the liver reported after up to 6 years of treatment when compared with the results of the initial studies. There was no evidence of adverse effects of lanthanum carbonate on the liver in patients who received treatment for up to 6 years.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lanthanum carbonate

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 件

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ ... The aim of this study was to determine whether long-term lanthanum exposure results in persistent alternations in nervous system function. Wistar rats were exposed to lanthanum chloride (LaCl(3)) through oral administration at 0, 0.1, 2 and 40mg/kg concentration from 4 weeks through 6 months of age. Morris water maze test showed that lanthanum exposure at 40mg/kg could significantly impair the behavioral performance. To fully investigate the neurotoxicological consequence of lanthanum exposure, brain elemental distributions and neurochemicals were also investigated. The distributions of brain elements such as Ca, Fe and Zn were significantly altered after lanthanum exposure. Moreover, 40mg/kg LaCl(3) significantly inhibited the activity of Ca(2+)-ATPase; the function of the central cholinergic system was also noticeably disturbed and the contents of some monoamines neurotransmitters were significantly decreased. These findings indicate that chronic exposure to lanthanum could possibly impair the learning ability and this deficit may be possibly attributed to the disturbance of the homeostasis of trace elements, enzymes and neurotransmitter systems in brain. ... /Lanthanum chloride/

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Oral administration of lanthanum carbonate to rats for up to 104 weeks, at doses up to 1500 mg of the salt per kg/day (2.5 times the maximum recommended daily human dose (MRHD) on a mg/sq m basis) revealed no evidence of carcinogenic potential.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ In the mouse, oral administration of lanthanum carbonate for up to 99 weeks, at a dose of 1500 mg/kg/day was associated with an increased incidence of glandular stomach adenomas in male mice.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Lanthanum carbonate, at doses up to 2000 mg/kg/day, did not affect fertility or mating performance of male or female rats. In pregnant rats, oral administration of lanthanum carbonate at doses as high as 2000 mg/kg/day resulted in no evidence of harm to the fetus.

For more Non-Human Toxicity Excerpts (Complete) data for Lanthanum Carbonate (8 total), please visit the HSDB record page.

Populations at Special Risk · 1 件

While growth abnormalities were not identified in long-term animal studies, lanthanum was deposited into developing bone including growth plate. The consequences of such deposition in developing bone in pediatric patients are unknown. Therefore, the use of lanthanum carbonate in this population is not recommended.

Antidote and Emergency Treatment · 3 件

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl lanthanum carbonate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
3
tsca
Yes
risk_code
36/37/38
hazard_code
Xi
safety_code
26-37/39
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
ストレージクラス
11 - Combustible Solids
Biological Half-Life · 3 件

The elimination half-life of lanthanum in patients undergoing dialysis was 53 hours following discontinuation of therapy.

Lanthanum was cleared from plasma following discontinuation of therapy with an elimination half-life 53 hours.

... Estimates of elimination half-life from bone ranged from 2.0 to 3.6 years.

Metabolism/Metabolites · 2 件

Lanthanum does not undergo metabolism.

Lanthanum is not metabolized and is not a substrate of CYP450. In vitro metabolic inhibition studies showed that lanthanum at concentrations of 10 and 40 ug/mL does not have relevant inhibitory effects on any of the CYP450 isoenzymes tested (1A2, 2C9/10, 2C19, 2D6, and 3A4/5).

FDA Pharmacological Classification · 2 件

LANTHANUM CARBONATE

Phosphate Chelating Activity [MoA]; Phosphate Binder [EPC]

Absorption, Distribution and Excretion · 6 件

The bioavailability of lanthanum carbonate following oral administration is exceedingly low (<0.002%), with a mean Cmax of 1.0 ng/mL and average serum concentration of 0.6 ng/mL. The timing of food intake relative to lanthanum administration (during and 30 minutes after food intake) has a negligible effect on the systemic level of lanthanum.

No information is available regarding the mass balance of lanthanum in humans after oral administration. In rats and dogs, the mean recovery of lanthanum after an oral dose was about 99% and 94%, respectively, and was essentially all from feces. Biliary excretion is the predominant route of elimination for circulating lanthanum in rats.

In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 μg), renal clearance was less than 2% of total plasma clearance.

Lanthanum is minimally absorbed from the GI tract following oral administration; bioavailability is less than 0.002%. In patients receiving therapeutic dosages of lanthanum for up to 2 years, mean plasma concentrations of the drug remained low (ie, 1.1 ng/mL or less).

Following single or multiple dose oral administration of lanthanum carbonate to healthy subjects, the concentration of lanthanum in plasma was very low. Following oral administration in ESRD patients, the mean lanthanum Cmax was 1.0 ng/mL. During long-term administration (52 weeks) in ESRD patients, the mean lanthanum concentration in plasma was approximately 0.6 ng/mL. There was minimal increase in plasma lanthanum concentrations with increasing doses within the therapeutic dose range. The effect of food on the bioavailability of lanthanum carbonate has not been evaluated, but the timing of food intake relative to lanthanum administration (during and 30 minutes after food intake) has a negligible effect on the systemic level of lanthanum

In vitro, lanthanum is highly bound (>99%) to human plasma proteins, including human serum albumin, alpha1-acid glycoprotein, and transferrin. Binding to erythrocytes in vivo is negligible in rats.

用途と製造

Uses · 2 件

THERAPEUTIC CATEGORY: Treatment of hyperphosphatemia

MEDICATION

U.S. Production · 3 件

2023: 1,000,000 - <5,000,000 lb

Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#7426]

Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#7427]

Consumer UsesCatalyst
Industry UsesOther
Formulations/PreparationsFormulations: (AHFS, 2009)
General Manufacturing Information · 2 件

Paint and Coating Manufacturing

Carbonic acid, lanthanum(3+) salt (3:2): ACTIVE

応用分野

用途高純度金属化合物。高純度ランタン化合物合成原料。

使用Lanthanum Carbonate Hydrate is used as a staring material in lanthanum chemistry. It is used in the medical industry as a phosphate binder.

上流・下流製品情報

下流製品

トリフルオロメタンスルホン酸ランタン(III)